Jingxian Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingxian Li has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- E. Du
Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University
1 shared publication - Qiang Su
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University
1 shared publication - Shuai Li
Department of Anorectal Surgery, The Second Hospital of Tianjin Medical University, Tianjin, China
1 shared publication - Wei Huang
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University
1 shared publication - Wei Wang
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University
1 shared publication - Yuanjiong Qi
Department of Urology, Tianjin Institute of Urology, The second hospital of Tianjin Medical University, Tianjin, 300211, China.
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 17 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 4911-4931
Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study
Background: Cancer-associated fibroblasts (CAFs) are found in primary and advanced tumours. They are primarily involved in tumour progression through complex mechanisms with other types of cells in the tumour microenvironment. However, essential fibroblasts-related genes (FRG) in bladder cancer still need to be explored, and there is a shortage of an ideal predictive model or molecular subtype for the progression and immune therapeutic assessment for bladder cancer, especially muscular-invasive bladder cancer based on the FRG. Materials and methods: CAF-related genes of bladder cancer were identified by analysing single-cell RNA sequence datasets, and bulk transcriptome datasets and gene signatures were used to characterize them. Then, 10 types of machine learning algorithms were utilised to determine the hallmark FRG and construct the FRG index (FRGI) and subtypes. Further molecular subtypes combined with CD8+ T-cells were established to predict the prognosis and immune therapy response. Results: Fifty-four BLCA-related FRG were screened by large-scale scRNA-sequence datasets. The machine learning algorithm established a 3-genes FRGI. High FRGI represented a worse outcome. Then, FRGI combined clinical variables to construct a nomogram, which shows high predictive performance for the prognosis of bladder cancer. Furthermore, the BLCA datasets were separated into two subtypes – fibroblast hot and cold types. In five independent BLCA cohorts, the fibroblast hot type showed worse outcomes than the cold type. Multiple cancer-related hallmark pathways are distinctively enriched in these two types. In addition, high FRGI or fibroblast hot type shows a worse immune therapeutic response. Then, four subtypes called CD8-FRG subtypes were established under the combination of FRG signature and activity of CD8+ T-cells, which turned out to be effective in predicting the prognosis and immune therapeutic response of bladder cancer in multiple independent datasets. Pathway enrichment analysis, multiple gene signatures, and epigenetic alteration characterize the CD8-FRG subtypes and provide a potential combination strategy method against bladder cancer. Conclusions: In summary, the authors established a novel FRGI and CD8-FRG subtype by large-scale datasets and organised analyses, which could accurately predict clinical outcomes and immune therapeutic response of BLCA after surgery.
- 17 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 4911-4931
Top Cited PapersOpen AccessSingle-cell and bulk RNA-sequence identified fibroblasts signature and CD8 + T-cell - fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine learning: bioinformatics multi-omics study
Background: Cancer-associated fibroblasts (CAFs) are found in primary and advanced tumours. They are primarily involved in tumour progression through complex mechanisms with other types of cells in the tumour microenvironment. However, essential fibroblasts-related genes (FRG) in bladder cancer still need to be explored, and there is a shortage of an ideal predictive model or molecular subtype for the progression and immune therapeutic assessment for bladder cancer, especially muscular-invasive bladder cancer based on the FRG. Materials and methods: CAF-related genes of bladder cancer were identified by analysing single-cell RNA sequence datasets, and bulk transcriptome datasets and gene signatures were used to characterize them. Then, 10 types of machine learning algorithms were utilised to determine the hallmark FRG and construct the FRG index (FRGI) and subtypes. Further molecular subtypes combined with CD8+ T-cells were established to predict the prognosis and immune therapy response. Results: Fifty-four BLCA-related FRG were screened by large-scale scRNA-sequence datasets. The machine learning algorithm established a 3-genes FRGI. High FRGI represented a worse outcome. Then, FRGI combined clinical variables to construct a nomogram, which shows high predictive performance for the prognosis of bladder cancer. Furthermore, the BLCA datasets were separated into two subtypes – fibroblast hot and cold types. In five independent BLCA cohorts, the fibroblast hot type showed worse outcomes than the cold type. Multiple cancer-related hallmark pathways are distinctively enriched in these two types. In addition, high FRGI or fibroblast hot type shows a worse immune therapeutic response. Then, four subtypes called CD8-FRG subtypes were established under the combination of FRG signature and activity of CD8+ T-cells, which turned out to be effective in predicting the prognosis and immune therapeutic response of bladder cancer in multiple independent datasets. Pathway enrichment analysis, multiple gene signatures, and epigenetic alteration characterize the CD8-FRG subtypes and provide a potential combination strategy method against bladder cancer. Conclusions: In summary, the authors established a novel FRGI and CD8-FRG subtype by large-scale datasets and organised analyses, which could accurately predict clinical outcomes and immune therapeutic response of BLCA after surgery.
- Open Access
- 11 November 2022
- Published by Springer Nature in Research Square
A multi-omics analysis and clinical relevance of regualted cell death in bladder cancer
The dysfunction of regulated cell death (RCD) could cause human diseases such as cancer, neurodegeneration, autoimmune diseases, and infectious diseases. Recent studies have indicated that RCD has closely functional interaction. Our study aimed to explore the cross-talk, genetic alteration, functions, mechanism, and cluster relevance of the several major types of RCD, including apoptosis, ferroptosis, pyroptosis, necroptosis, autophagy-dependent cell death, in bladder cancer (BLCA). Through analyzing the public database, we found that the genes representing these five RCD types showed complex cross-talk in mRNA, protein levels, somatic mutation, and DNA copy number in BLCA. The mRNA expression of regulated cell death genes (RCDGs) was affected by DNA copy number, somatic mutation, DNA methylation, and RNA modification. Several RCDGs were essential for cell viability, and the expression of RCDGs was correlated with radiotherapeutic sensitivity and IC50 of chemotherapy drugs. Based on the expression of RCDGs, the BLCA patients were divided into two clusters. We found multiple immune-related pathways significantly enriched in cluster1/cluster2. In addition, the patients' prognosis, immune therapy response, and drug sensitivity in these two clusters were significantly different. Through the comparison between the RCD clusters and consensus cluster, we found that RCD cluster1 mainly correlated with the basal squamous cluster, and the RCD cluster2 mainly correlated with the luminal cluster. Through the weighted gene co-expression network analysis (WGCNA), we identified the high correlation RCDGs with cluster1/cluster2. We found that most cluster1-RCDGs were correlated with poor prognosis for patients, and most prognosis-protection genes correlated with cluster2. Besides, the expression of these prognosis-related RCDGs showed different distribution patterns in basal/luminal subtypes. In summary, our study conducted a comprehensive analysis of RCDGs in BLCA, which provided the foundation for subsequent experiments and therapeutic options.
- 11 November 2022
- Published by Springer Nature in Research Square
Open AccessA multi-omics analysis and clinical relevance of regualted cell death in bladder cancer
The dysfunction of regulated cell death (RCD) could cause human diseases such as cancer, neurodegeneration, autoimmune diseases, and infectious diseases. Recent studies have indicated that RCD has closely functional interaction. Our study aimed to explore the cross-talk, genetic alteration, functions, mechanism, and cluster relevance of the several major types of RCD, including apoptosis, ferroptosis, pyroptosis, necroptosis, autophagy-dependent cell death, in bladder cancer (BLCA). Through analyzing the public database, we found that the genes representing these five RCD types showed complex cross-talk in mRNA, protein levels, somatic mutation, and DNA copy number in BLCA. The mRNA expression of regulated cell death genes (RCDGs) was affected by DNA copy number, somatic mutation, DNA methylation, and RNA modification. Several RCDGs were essential for cell viability, and the expression of RCDGs was correlated with radiotherapeutic sensitivity and IC50 of chemotherapy drugs. Based on the expression of RCDGs, the BLCA patients were divided into two clusters. We found multiple immune-related pathways significantly enriched in cluster1/cluster2. In addition, the patients' prognosis, immune therapy response, and drug sensitivity in these two clusters were significantly different. Through the comparison between the RCD clusters and consensus cluster, we found that RCD cluster1 mainly correlated with the basal squamous cluster, and the RCD cluster2 mainly correlated with the luminal cluster. Through the weighted gene co-expression network analysis (WGCNA), we identified the high correlation RCDGs with cluster1/cluster2. We found that most cluster1-RCDGs were correlated with poor prognosis for patients, and most prognosis-protection genes correlated with cluster2. Besides, the expression of these prognosis-related RCDGs showed different distribution patterns in basal/luminal subtypes. In summary, our study conducted a comprehensive analysis of RCDGs in BLCA, which provided the foundation for subsequent experiments and therapeutic options.